Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. It is generally a slow and progressive condition resulting from various causes such as diabetes, high blood pressure, glomerulonephritis, polycystic kidney disease, and others. As kidneys lose their ability to filter waste from the blood, harmful levels of fluid, electrolytes, and wastes can accumulate in the body. Common symptoms include fatigue, loss of appetite, and nausea. Chronic kidney disease drugs help slow the progression of kidney damage and reduce risk of cardiovascular disease. Some main drug types used for chronic kidney disease treatment include ACE inhibitors, angiotensin II receptor blockers, erythropoiesis-stimulating agents (ESAs), calcium channel blockers, beta-blockers, diuretics, phosphate binders, calcimimetics, and others.
The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the chronic kidney disease drugs market is the rise in pipeline drugs and therapies. Many pharmaceutical companies are investing heavily in R&D to develop novel therapies for CKD with improved efficacy and reduced side effects. For instance, Reata Pharmaceuticals is developing omaveloxolone, a first-in-class Nrf2 activator, for the treatment of CKD. Another trend is the growing preference for combination therapies over monotherapies. Combining drugs that act via different mechanisms helps achieve better renal as well as cardiovascular protection. Biosimilars are also gaining traction as they provide comparable efficacy at lower costs. Further, growing geriatric population, increasing incidence of diabetes and hypertension, rising awareness about early detection of CKD, and better reimbursement policies are some other factors fueling the chronic kidney disease drugs market growth.
Threat of new entrants: The chronic kidney disease drugs market has moderate threats of new entrants due to high capital requirements for R&D and manufacturing. However, opportunities exist for specialized drugs targeting specific end-users.
Bargaining power of buyers: The bargaining power of buyers is high due to the presence of many manufacturers and suppliers providing substitutable chronic kidney disease drugs globally.
Bargaining power of suppliers: The bargaining power of suppliers is moderate owing to the availability of standardized raw materials required to produce chronic kidney disease drugs.
Threat of new substitutes: The threat of substitutes is low to moderate due to limited availability of alternative treatment options for chronic kidney disease.
Competitive rivalry: High due to the presence of many global and regional players competing on efficacy and cost.
The global chronic kidney disease drugs market size is expected to witness high growth, exhibiting a CAGR of 4.5% over the forecast period, due to increasing prevalence of chronic kidney disease. North America is expected to dominate the global market owing to new product launches and approvals.
The global chronic kidney disease drugs market size for 2023 is US$ 13,220.0 Mn. Regional analysis related content comprises Regional analysis related content (Write regional analysis in 200 words explanation fastest growing and dominating region.) The Asia Pacific region is expected to witness the fastest growth in the market over the forecast period. Expanding healthcare infrastructure and increasing medical spending in China and India are expected to drive the APAC chronic kidney disease drugs market.
Key players related content comprises Key players operating in the chronic kidney disease drugs market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it